FDA approves cablivi for rare blood-clotting disorder

FDA approves cablivi for rare blood-clotting disorder
(HealthDay)—Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP).

"Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body," Richard Pazdur, M.D., director of the FDA Oncology Center of Excellence, said in a statement. "Even after days or weeks of this treatment, as well as taking drugs that suppress the , many patients will have a recurrence of aTTP."

Cablivi is the first targeted treatment that inhibits and provides a new treatment option for patients that may reduce recurrences. Cablivi was evaluated in clinical studies involving 145 people. Those treated with Cablivi had fewer instances of aTTP-related death, the FDA said.

Common side effects include headache and bleeding of the nose or gums. Cablivi's prescribing information includes a warning about the risk for severe bleeding. Health care providers should closely monitor patients who also take anticoagulants, the FDA said.

The drug is produced by Ablynx, based in Belgium.


Explore further

FDA approves novel treatment for hairy cell leukemia

More information: More Information

Health News Copyright © 2019 HealthDay. All rights reserved.

Citation: FDA approves cablivi for rare blood-clotting disorder (2019, February 7) retrieved 23 February 2019 from https://medicalxpress.com/news/2019-02-fda-cablivi-rare-blood-clotting-disorder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more